

Pharmaceutical Excipients Global Market - Forecast To 2029

https://marketpublishers.com/r/P9741C588EFEN.html

Date: February 2023

Pages: 675

Price: US\$ 4,950.00 (Single User License)

ID: P9741C588EFEN

Abstracts

Pharmaceutical excipients are inactive substances in the drug which help in modulating the solubility, bioavailability, and stability of active substances for formulating final drug dosage forms. The excipients form the major part of any medicinal product and the proportion of it, when compared to Active Pharmaceutical Ingredient (API), exceeds two to three folds in any pharmaceutical preparations. Hence, various characteristics such as functionality, regulatory status, sources, cost, consistency, bioavailability, physicochemical properties, stability, pharmacokinetic parameters, etc. play a major role in determining the suitability of a substance as an excipient.

As estimated by IQ4I Research, the pharmaceutical excipients global market is expected to grow at mid single-digit CAGR from 2022 to 2029 to reach \$15,439.6 million by 2029. The pharmaceutical excipients market is segmented based on source, products, functionality, and dosage forms.

The pharmaceutical excipients market based on the source is segmented as animal-based, plant-based, mineral-based, and synthetic-based excipients. Among them, plant-based excipients contributed the largest revenue in 2022 and it is the fastest growing segment at a high single digit CAGR from 2022 to 2029 due to plant-based excipients are cost-effective, low toxic with the better patient tolerance, bio-compatible and they are easily available. Based on products, excipients are segmented into inorganic chemicals, organic chemicals, and others. The organic chemical segment contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029 due to the use of these excipients in majorly all of the pharmaceutical formulations as they offer advantages such as increased efficacy in oral delivery of poorly soluble molecules along with increased compressibility and flowability properties.



The inorganic chemical excipients market based on product type is further divided into calcium salts, halites, metallic oxides, silicates, and other inorganic chemicals, among which metallic oxides contributed a major revenue in 2022 and the calcium salts segment is the fastest growing segment with a high single digit CAGR 2022 to 2029. Calcium salts are further sub-segmented into calcium phosphate, calcium carbonate, and others, among which, calcium phosphate contributed the largest revenue in 2022, and the calcium carbonate segment is expected to grow at a high single digit CAGR from 2022 to 2029. Calcium carbonate is further classified into GCC and PCC, among which PCC contributed the largest revenue in 2022 and it is expected to grow at a high single digit CAGR from 2022 to 2029. The metallic oxides segment is further segmented into titanium dioxide and others (Iron Oxide, Magnesium Oxide & Aluminum Hydroxide). Titanium Dioxide contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The organic chemical excipients market by product type is further divided into carbohydrates, petrochemicals, oleochemicals, proteins, and other organic chemicals. Carbohydrates contributed major revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The Carbohydrate excipients market based on product type is further segmented into sugar, starch, and cellulose, among which, cellulose contributed the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029. The sugar segment is further divided into actual sugar, sugar alcohol, and artificial sweeteners, where actual sugar contributed the largest revenue in 2022 and the sugar alcohol segment is expected to grow at high single digit CAGR from 2022 to 2029.

The actual sugar segment is further sub-segmented into lactose, sucrose, and dextrose, where lactose contributed the largest revenue in 2022, and the sucrose segment is expected to grow at high single digit CAGR from 2022 to 2029. The sugar alcohol segment is further classified into sorbitol, mannitol, and other sugar alcohols, where mannitol contributed the largest revenue in 2022 and it is expected to grow at high single digit CAGR from 2022 to 2029. The starch segment is further divided into modified starch, dried starch, and converted starch, where modified starch contributed the largest revenue in 2022 and dried starch is expected to grow at mid single digit CAGR from 2022 to 2029. The cellulose segment is further sub-segmented into cellulose ethers, cellulose esters, croscarmellose sodium, and microcrystalline cellulose, where microcrystalline cellulose holds the largest revenue in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029.



The petrochemical excipients market based on product type is further segmented into glycols, povidones, mineral hydrocarbons, acrylic polymers, and other petrochemical excipients. Glycol contributed the largest revenue in 2022 and povidones are the fastest growing segment with a mid single digit CAGR from 2022 to 2029. The Glycol is further segmented into Polyethylene Glycol and Propylene Glycol, where Polyethylene Glycol contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The Oleochemicals excipients market based on product type is further segmented into Fatty Alcohols, Mineral stearates, Glycerin, and Other Oleochemical Excipients. Fatty Alcohol contributed the largest revenue in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029 while mineral stearates is the fastest growing segment with mid single digit CAGR from 2022 to 2029.

Other excipients market based on product type is further segmented into the water for injections and purified water. Water for injections contributed the largest revenue in 2022 and it is expected to grow at low single digit CAGR from 2022 to 2029.

The pharmaceutical excipients market based on functionality is segmented as preservatives, solvents, binders & adhesives, fillers & diluents, suspending agents, coatings, solubilizers, disintegrants, colorants, flavoring & sweeteners, lubricants & glidants, and others. Binders & Adhesives contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The pharmaceutical excipients market based on dosage forms is segmented as solid dosage forms, injectables and semisolids, and others. Solid dosage forms hold the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029. Based on the manufacturing process solid dosage forms are segmented into granulation and direct compression. Granulation contributed the largest revenue in 2022 and direct compression is expected to grow at mid single digit CAGR from 2022 to 2029. Some of the factors driving the solid dosage forms market are cost-effectiveness, solid dosage provides increased physical and chemical stability, controlled-release options, and superior ease of handling.

The pharmaceutical excipients market based on region is segmented into North America (U.S. and the Rest of North America), Europe (Germany, France, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & others). North America contributed the largest revenue in 2022 due to increasing demand for functional



excipients, implementation of novelties like lipid nano particles, increasing usage of oral solid dosage forms, increasing incidence of chronic disorders, elderly population, and favorable reimbursement scenario for drugs. Also, technological innovations in the manufacturing procedures of excipients have propelled the market growth in North America. Stringent cGMP regulatory guidelines have resulted in a rising demand for high-grade excipients. In North America, the United States and Canada are the major markets observed due to its increasing investments in biopharmaceuticals, the growth in the demand for customized products, and advancements in multifunctional excipients in the market. Excipients manufacturers in developing countries face major challenges to develop a product with quality at an affordable price, due to the lower price of excipients and a large number of producers, which creates a price-sensitive market. Some manufacturers may compromise the quality of the product to keep prices low and boost sales, while some of the manufacturers having a larger market for their products, can sell their higher volume excipients at a slightly lower price. Asia-Pacific is the fastest-growing segment and is expected to grow at high single digit CAGR from 2022 to 2029.

Even though excipients are considered an essential component and have a major role in the drug delivery system, the lack of specific regulations, standardized tests, protocols, and guidelines is affecting the quality evaluation of excipients. Excipient manufacturers should follow WHO initiatives (GTDP, GMP), ICH Q3D, ICH Q1B, QBD requirements, PDG monograph harmonization, Good pharmacopeia practices, US FDA FDASIA, Title VII, E-DMF, and EU FMD. These regulations are compelling pharmaceutical manufacturers to develop a quality product by adopting various standard testing methods. EXCiPACT is a pharmaceutical excipients certification scheme to provide independent third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide. EXiPACT certification enables to demonstrate that operations meet the minimum Good Manufacturing Practice (GMP) and/or Good Distribution Practice (GDP) requirements for excipients.

Presently, there is demand for the development of novel excipients with technological advancements like new chemical entity excipients, new chemically modified grade excipients, and existing excipients with the various route of administration and coprocessed excipients. These novel excipients increase the scope for the development of new formulations and drug delivery systems which are a major gain for the industry, but the high cost and lengthy developmental process along with the safety and quality issues are delaying the excipients approval. Combinational excipients are mostly preferred by the manufacturers as the single excipients do not meet all the functional requirements such as high solubility, stability, and bioavailability.



The pharmaceutical excipients global market is highly competitive hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the key players contributing at the global level to pharmaceutical excipients market growth are IFF (U.S.), Ashland, Inc. (U.S.), BASF SE (Germany), DFE Pharma (Germany), Evonik Industries AG (Germany), Croda International Plc (U.K.), Merck KGAA (Germany), Roquette (France), Colorcon (U.S.), and Asahi Kasei (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:



Rest of the World (RoW)

Brazil



Rest of Latin America

The Middle East and Others



Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION

- 2.1 KEY TAKEAWAYS
- 2.2 SCOPE OF THE REPORT
- 2.3 REPORT DESCRIPTION
- 2.4 MARKETS COVERED
- 2.5 STAKEHOLDERS
- 2.6 RESEARCH METHODOLOGY
 - 2.6.1 MARKET SIZE ESTIMATION
 - 2.6.2 MARKET BREAKDOWN AND DAT TRIANGULATION
 - 2.6.3 SECONDARY SOURCES
 - 2.6.4 KEY DATA POINTS FROM SECONDARY SOURCES
 - 2.6.5 PRIMARY SOURCES
 - 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
 - 2.6.7 ASSUMPTIONS

3 MARKET ANALYSIS

- 3.1 INTRODUCTION
- 3.2 MARKET SEGMENTATION
- 3.3 FACTORS INFLUENCING MARKET
 - 3.3.1 DRIVERS AND OPPORTUNITIES
 - 3.3.1.1 Growth in generics and biosimilar drugs
 - 3.3.1.2 Increasing demand for oral solid dosage form(osdf) excipients
 - 3.3.1.3 Increasing demand for multifunctional excipients
 - 3.3.1.4 Drug-coated medical devices
 - 3.3.1.5 Increasing demand for solubility-enhancing excipients
 - 3.3.1.6 Rising demand for sustained or controlled-release formulations
 - 3.3.1.7 Increasing prevalence of chronic diseases, rise in the aging population
 - 3.3.2 RESTRAINTS AND THREATS
 - 3.3.2.1 Adverse reactions of excipients
 - 3.3.2.2 Contamination in formulations
 - 3.3.2.3 Supply chain issues and geopolitical scenarios impacting the market
 - 3.3.2.4 Challenges in excipients innovation
- 3.4 REGULATORY AFFAIRS



- 3.4.1 THE U.S.
- **3.4.2 EUROPE**
- **3.4.3 JAPAN**
- 3.4.4 CHINA
- 3.4.5 INDIA
- 3.4.6 REST OF THE WORLD
- 3.4.7 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
 - 3.4.7.1 ISO 9001: 2015 Quality Management System
- 3.4.8 INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL (IPEC FEDERATION)
 - 3.4.9 PHARMACEUTICAL QUALITY GROUP (PQG)
 - 3.4.10 EXCIPACT-GMP/GDP CERTIFICATION
- 3.5 PORTER'S FIVE FORCE ANALYSIS
 - 3.5.1 THREAT OF NEW ENTRANTS
 - 3.5.2 THREAT OF SUBSTITUTES
 - 3.5.3 BARGAINING POWER OF SUPPLIERS
 - 3.5.4 BARGAINING POWER OF BUYERS
 - 3.5.5 COMPETITIVE RIVALRY
- 3.6 SUPPLY CHAIN ANALYSIS
- 3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
 - 3.7.1 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE ANALYSIS
- 3.8 NOVEL EXCIPIENTS
- 3.9 POLYMER-BASED EXCIPIENTS
- 3.10 LIPID-BASED EXCIPIENTS
- 3.11 CARBOXYMETHYL CELLULOSE (CMC) PRODUCTION FROM
- LIGNOCELLULOSIC CORN AGRO-WASTE
- 3.12 CONTAMINATION IN EXCIPIENTS
 - 3.12.1 (N-NITROSODIMETHYLAMINE)NDMA CONTAMINATION IN MEDICINES
 - 3.12.2 PHTHALATE EXCIPIENTS
- 3.13 CHANGING LANDSCAPE OF THE EXCIPIENTS MARKET
- 3.14 PHARMACEUTICAL EXCIPIENTS-FUNDING SCENARIO
- 3.15 PHARMACEUTICAL EXCIPIENTS-ACQUISITION
- 3.16 MOLECULE TYPE
- 3.17 DRUG MASTER FILING (DMF)
- 3.18 EXCIPIENTS BASED ON MOLECULE TYPE
- 3.19 EXCIPIENTS PRICING
- 3.20 GLOBAL PHARMACEUTICAL EXCIPIENTS PRODUCTION VOLUME
- 3.21 EXCIPIENTS USED IN THE GLOBAL TOP 115 SELLING DRUGS BASED ON REVENUE



3.22 EXCIPIENT MANUFACTURER'S REVENUE, PRODUCT, FUNCTIONALITY AND DOSAGE FORMS

4 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON SOURCE

- 4.1 INTRODUCTION
- 4.2 ANIMAL-BASED EXCIPIENTS
- 4.3 PLANT-BASED EXCIPIENTS
- 4.4 MINERAL-BASED EXCIPIENTS
- 4.5 SYNTHETIC-BASED EXCIPIENTS

5 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON PRODUCT

- 5.1 INTRODUCTION
- 5.2 INORGANIC EXCIPIENTS
 - 5.2.1 CALCIUM SALT EXCIPIENTS
 - 5.2.1.1 Calcium phosphate excipients
 - 5.2.1.2 Calcium carbonate excipients
 - 5.2.1.2.1 GCC excipients
 - 5.2.1.2.2 PCC excipients
 - 5.2.1.3 Other calcium salt excipients
 - **5.2.2 HALITE EXCIPIENTS**
 - 5.2.3 METALLIC OXIDE EXCIPIENTS
 - 5.2.3.1 Titanium dioxide excipients
 - 5.2.3.2 Other metallic oxides excipients
 - 5.2.4 SILICATE EXCIPIENTS
 - 5.2.5 OTHER INORGANIC CHEMICAL EXCIPIENTS
- 5.3 ORGANIC CHEMICAL EXCIPIENTS
 - 5.3.1 CARBOHYDRATE EXCIPIENTS
 - 5.3.1.1 Sugar excipients
 - 5.3.1.1.1 Actual sugar excipients
 - 5.3.1.1.1 Lactose excipients
 - 5.3.1.1.1.2 Sucrose excipients
 - 5.3.1.1.3 Dextrose excipients
 - 5.3.1.1.2 Sugar alcohol excipients
 - 5.3.1.1.2.1 Sorbitol excipients
 - 5.3.1.1.2.2 Mannitol excipients
 - 5.3.1.1.2.3 Other sugar alcohols excipients
 - 5.3.1.1.3 Artificial sweetener excipients



5.	.3.	1	.2	Starch	exci	pients
----	-----	---	----	--------	------	--------

- 5.3.1.2.1 Modified starch excipients
- 5.3.1.2.2 Dried starch excipients
- 5.3.1.2.3 Converted starch excipients
- 5.3.1.3 Cellulose excipients
 - 5.3.1.3.1 Cellulose ether excipients
 - 5.3.1.3.2 Cellulose ester excipients
 - 5.3.1.3.3 Croscarmellose sodium excipients
 - 5.3.1.3.4 Microcrystalline cellulose excipients

5.3.2 PETROCHEMICAL EXCIPIENTS

- 5.3.2.1 Glycol excipients
 - 5.3.2.1.1 Polyethylene glycol excipients
 - 5.3.2.1.2 Propylene glycol excipients
- 5.3.2.2 Povidone excipients
- 5.3.2.3 Mineral hydrocarbon excipients
- 5.3.2.4 Acrylic polymer excipients
- 5.3.2.5 Other petrochemical excipients
- 5.3.3 OLEOCHEMICAL EXCIPIENTS
 - 5.3.3.1 Fatty alcohol excipients
 - 5.3.3.2 Mineral stearate excipients
 - 5.3.3.3 Glycerin excipients
 - 5.3.3.4 Other oleochemical excipients
- 5.3.4 PROTEIN EXCIPIENTS
- 5.3.5 OTHER ORGANIC CHEMICAL EXCIPIENTS
- **5.4 OTHER EXCIPIENTS**
 - 5.4.1 WATER FOR INJECTION
 - 5.4.2 PURIFIED WATER EXCIPIENT

6 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON FUNCTIONALITY

- **6.1 INTRODUCTION**
- **6.2 PRESERVATIVE EXCIPIENTS**
- **6.3 SOLVENT EXCIPIENTS**
- 6.4 BINDER & ADHESIVE EXCIPIENTS
- 6.5 FILLER & DILUENT EXCIPIENTS
- **6.6 SUSPENDING AGENT EXCIPIENTS**
- 6.7 COATING EXCIPIENTS
- **6.8 SOLUBILIZER EXCIPIENTS**



- **6.9 DISINTEGRANT EXCIPIENTS**
- 6.10 COLORANT, FLAVORING & SWEETENER EXCIPIENTS
- 6.11 LUBRICANT & GLIDANT EXCIPIENTS
- 6.12 OTHER EXCIPIENTS

7 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON DOSAGE FORMS

- 7.1 INTRODUCTION
- 7.2 SOLID DOSAGE FORMS
- 7.2.1 SOLID DOSAGE FORM GLOBAL MARKET, BASED ON MANUFACTURING PROCESS
 - 7.2.1.1 Introduction
 - 7.2.1.2 Granulation
 - 7.2.1.3 Direct compression
- 7.3 INJECTABLES
- 7.4 SEMISOLIDS AND OTHER DOSAGE FORMS

8 REGIONAL ANALYSIS

- 8.1 INTRODUCTION
- 8.2 NORTH AMERICA
 - 8.2.1 U.S.
 - 8.2.2 REST OF NORTH AMERICA
- 8.3 EUROPE
 - 8.3.1 GERMANY
 - **8.3.2 FRANCE**
 - 8.3.3 ITALY
- 8.3.4 REST OF EUROPE
- 8.4 APAC
 - 8.4.1 CHINA
 - 8.4.2 INDIA
 - 8.4.3 JAPAN
 - 8.4.4 REST OF APAC
- 8.5 ROW
 - 8.5.1 BRAZIL
 - 8.5.2 REST OF LATAM
 - 8.5.3 MIDDLE EAST & OTHERS



9 MAJOR COMPANIES

- 9.1 ASHLAND, INC.
 - 9.1.1 OVERVIEW
 - 9.1.2 FINANCIALS
 - 9.1.3 PRODUCT PORTFOLIO
 - 9.1.4 KEY DEVELOPMENTS
 - 9.1.5 BUSINESS STRATEGY
 - 9.1.6 SWOT ANALYSIS
- 9.2 ASSOCIATED BRITISH FOODS, PLC (SPI PHARMA)
 - 9.2.1 OVERVIEW
 - 9.2.2 FINANCIALS
 - 9.2.3 PRODUCT PORTFOLIO
 - 9.2.4 KEY DEVELOPMENTS
 - 9.2.5 BUSINESS STRATEGY
 - 9.2.6 SWOT ANALYSIS
- 9.3 BASF SE
 - 9.3.1 OVERVIEW
 - 9.3.2 FINANCIALS
 - 9.3.3 PRODUCT PORTFOLIO
 - 9.3.4 KEY DEVELOPMENTS
 - 9.3.5 BUSINESS STRATEGY
 - 9.3.6 SWOT ANALYSIS
- 9.4 CRODA INTERNATIONAL, PLC
 - 9.4.1 OVERVIEW
 - 9.4.2 FINANCIALS
 - 9.4.3 PRODUCT PORTFOLIO
 - 9.4.4 KEY DEVELOPMENTS
 - 9.4.5 BUSINESS STRATEGY
 - 9.4.6 SWOT ANALYSIS
- 9.5 DOW CHEMICAL
 - 9.5.1 OVERVIEW
 - 9.5.2 FINANCIALS
 - 9.5.3 PRODUCT PORTFOLIO
 - 9.5.4 KEY DEVELOPMENTS
 - 9.5.5 BUSINESS STRATEGY
 - 9.5.6 SWOT ANALYSIS
- 9.6 DUPONT DE NEMOURS, INC
 - 9.6.1 OVERVIEW



- 9.6.2 FINANCIALS
- 9.6.3 PRODUCT PORTFOLIO
- 9.6.4 KEY DEVELOPMENTS
- 9.6.5 BUSINESS STRATEGY
- 9.6.6 SWOT ANALYSIS
- 9.7 EVONIK INDUSTRIES, AG
 - 9.7.1 OVERVIEW
 - 9.7.2 FINANCIALS
 - 9.7.3 PRODUCT PORTFOLIO
 - 9.7.4 KEY DEVELOPMENTS
 - 9.7.5 BUSINESS STRATEGY
 - 9.7.6 SWOT ANALYSIS
- 9.8 FRIESLAND CAMPINA GERMANY GMBH(DFE PHARMA)
 - 9.8.1 OVERVIEW
 - 9.8.2 FINANCIALS
 - 9.8.3 PRODUCT PORTFOLIO
 - 9.8.4 KEY DEVELOPMENTS
 - 9.8.5 BUSINESS STRATEGY
 - 9.8.6 SWOT ANALYSIS
- 9.9 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
 - 9.9.1 OVERVIEW
 - 9.9.2 FINANCIALS
 - 9.9.3 PRODUCT PORTFOLIO
 - 9.9.4 KEY DEVELOPMENTS
 - 9.9.5 BUSINESS STRATEGY
 - 9.9.6 SWOT ANALYSIS
- 9.10 KERRY GROUP
 - **9.10.1 OVERVIEW**
 - 9.10.2 FINANCIALS
 - 9.10.3 PRODUCT PORTFOLIO
 - 9.10.4 KEY DEVELOPMENTS
 - 9.10.5 BUSINESS STRATEGY
 - 9.10.6 SWOT ANALYSIS



List Of Tables

LIST OF TABLES

TABLE 1 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 2 ESTIMATES OF THE PFIZER/BIONTECH (COMIRNATY) LIPID EXCIPIENTS REQUIRED (KG), AVERAGE SELLING PRICE (ASP) (\$) AND REVENUE GENERATED (\$MN) (2022)

TABLE 3 ESTIMATES OF THE MODERNA (SPIKEVAX) LIPID EXCIPIENTS REQUIRED (KG), AVERAGE SELLING PRICE (ASP) (\$) AND REVENUE GENERATED (\$MN) (2022)

TABLE 4 EXCIPIENTS PRICING

TABLE 5 GLOBAL PHARMACEUTICAL EXCIPIENTS REVENUE (\$MN), AVERAGE SELLING PRICE (\$/KG) AND PRODUCTION IN TONS, BASED ON PRODUCT (2022) TABLE 6 GLOBAL PHARMACEUTICAL EXCIPIENTS PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 7 EXCIPIENTS USED IN GLOBAL TOP-SELLING DRUGS (2021)

TABLE 8 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON SOURCE, (2021-2029) (\$MN)

TABLE 9 ANIMAL-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 10 PLANT-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 11 MINERAL-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 12 SYNTHETIC-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 13 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 14 PHARMACEUTICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 15 INORGANIC EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 16 INORGANIC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 17 INORGANIC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 18 CALCIUM SALT EXCIPIENTS GLOBAL PRODUCTION, BASED ON



PRODUCT, (2021-2029) (TONS)

TABLE 19 CALCIUM SALT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 20 CALCIUM SALT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 21 CALCIUM PHOSPHATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 22 CALCIUM CARBONATE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 23 CALCIUM CARBONATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 24 CALCIUM CARBONATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 25 GCC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 26 PCC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 27 OTHER CALCIUM SALT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 28 HALITE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 29 METALLIC OXIDE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 30 METALLIC OXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 31 METALLIC OXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 32 TITANIUM DIOXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 33 OTHER METALLIC OXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 34 SILICATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 35 OTHER INORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 36 ORGANIC CHEMICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT TYPE, (2021-2029) (TONS)

TABLE 37 ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)



TABLE 38 ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 39 CARBOHYDRATE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 40 CARBOHYDRATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 41 CARBOHYDRATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 42 SUGAR EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 43 SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 44 SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 45 ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 46 ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 47 LACTOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 48 SUCROSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 49 DEXTROSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 50 SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 51 SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 52 SORBITOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 53 MANNITOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION. (2021-2029) (\$MN)

TABLE 54 OTHER SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 55 ARTIFICIAL SWEETENER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 56 STARCH EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 57 STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON



PRODUCT, (2021-2029) (\$MN)

TABLE 58 STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 59 MODIFIED STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 60 DRIED STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 61 CONVERTED STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 62 CELLULOSE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 63 CELLULOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 64 CELLULOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 65 CELLULOSE ETHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 66 CELLULOSE ESTER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 67 CROSCARMELLOSE SODIUM EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 68 MICROCRYSTALLINE CELLULOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 69 PETROCHEMICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 70 PETROCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 71 PETROCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 72 GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 73 GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 74 POLYETHYLENE GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 75 PROPYLENE GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 76 POVIDONE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)



TABLE 77 MINERAL HYDROCARBON EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 78 ACRYLIC POLYMER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 79 OTHER PETROCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 80 OLEOCHEMICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)

TABLE 81 OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 82 OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 83 FATTY ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 84 MINERAL STEARATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 85 GLYCERIN EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 86 OTHER OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 87 PROTEIN EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 88 OTHER ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 89 OTHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 90 OTHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 91 WATER FOR INJECTION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 92 PURIFIED WATER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION. (2021-2029) (\$MN)

TABLE 93 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) (\$MN)

TABLE 94 PRESERVATIVE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 95 SOLVENT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION. (2021-2029) (\$MN)

TABLE 96 BINDER & ADHESIVE EXCIPIENTS GLOBAL MARKET REVENUE, BASED



ON REGION, (2021-2029) (\$MN)

TABLE 97 FILLER & DILUENT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 98 SUSPENDING AGENT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 99 COATING EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 100 SOLUBILIZER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 101 DISINTEGRANT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 102 COLORANT, FLAVORING & SWEETENER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 103 LUBRICANT & GLIDANT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 104 OTHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 105 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) (\$MN)

TABLE 106 SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 107 SOLID DOSAGE FORM GLOBAL MARKET, BASED ON MANUFACTURING PROCESS. (2021-2029) (\$MN)

TABLE 108 GRANULATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 109 DIRECT COMPRESSION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 110 INJECTABLES DOSAGE FORM GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 111 INJECTABLES DOSAGE FORM GLOBAL MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2021-2029) (\$MN)

TABLE 112 SEMISOLIDS AND OTHER DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 113 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) (\$MN)

TABLE 114 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) (\$MN)

TABLE 115 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)



TABLE 116 NORTH AMERICAN INORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 117 NORTH AMERICAN CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 118 NORTH AMERICAN CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 119 NORTH AMERICAN METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 120 NORTH AMERICAN ORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 121 NORTH AMERICAN CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 122 NORTH AMERICAN SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 123 NORTH AMERICAN ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 124 NORTH AMERICAN SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 125 NORTH AMERICAN STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 126 NORTH AMERICAN CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 127 NORTH AMERICAN PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 128 NORTH AMERICAN GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 129 NORTH AMERICAN OLEOCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 130 NORTH AMERICAN OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 131 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) (\$MN)

TABLE 132 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) (\$MN)

TABLE 133 NORTH AMERICAN SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) (\$MN)

TABLE 134 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 135 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE,



BASED ON SOURCE, (2021-2029) (\$MN)

TABLE 136 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 137 EUROPEAN INORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 138 EUROPEAN CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 139 EUROPEAN CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 140 EUROPEAN METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 141 EUROPEAN ORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 142 EUROPEAN CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 143 EUROPEAN SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 144 EUROPEAN ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 145 EUROPEAN SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 146 EUROPEAN STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 147 EUROPEAN CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 148 EUROPEAN PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 149 EUROPEAN GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 150 EUROPEAN OLEOCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 151 EUROPEAN OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 152 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) (\$MN)

TABLE 153 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) (\$MN)

TABLE 154 EUROPEAN SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) (\$MN)



TABLE 155 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 156 APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) (\$MN)

TABLE 157 APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 158 APAC INORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 159 APAC CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 160 APAC CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 161 APAC METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 162 APAC ORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 163 APAC CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 164 APAC SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 165 APAC ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 166 APAC SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 167 APAC STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 168 APAC CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 169 APAC PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 170 APAC GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 171 APAC OLEOCHEMICALS EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 172 APAC OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 173 APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) (\$MN)

TABLE 174 APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED



ON DOSAGE FORMS, (2021-2029) (\$MN)

TABLE 175 APAC SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) (\$MN)

TABLE 176 APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 177 ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) (\$MN)

TABLE 178 ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 179 ROW INORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 180 ROW CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 181 ROW CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 182 ROW METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 183 ROW ORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 184 ROW CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) (\$MN)

TABLE 185 ROW SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 186 ROW ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 187 ROW SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 188 ROW STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 189 ROW CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 190 ROW PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 191 ROW GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 192 ROW OLEOCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)

TABLE 193 ROW OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) (\$MN)



TABLE 194 ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) (\$MN)

TABLE 195 ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) (\$MN)

TABLE 196 ROW SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) (\$MN)

TABLE 197 ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) (\$MN)

TABLE 198 ASHLAND, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (\$MN)

TABLE 199 ASHLAND, INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) (\$MN)

TABLE 200 ASHLAND, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (\$MN)

TABLE 201 ASHLAND, INC.: LIFE SCIENCE GEOGRAPHY REVENUE, (2020-2022) (\$MN)

TABLE 202 ASSOCIATED BRITISH FOODS, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (\$MN)

TABLE 203 ASSOCIATED BRITISH FOODS, PLC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) (\$MN)

TABLE 204 ASSOCIATED BRITISH FOODS, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (\$MN)

TABLE 205 BASF SE: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) (\$MN)

TABLE 206 BASF SE: TOTAL REVENUE, BY SEGMENT, (2020-2022(Q2)) (\$MN)

TABLE 207 BASF SE: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022(Q2)) (\$MN)

TABLE 208 CRODA INTERNATIONAL, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) (\$MN)

TABLE 209 CRODA INTERNATIONAL, PLC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2)) (\$MN)

TABLE 210 CRODA INTERNATIONAL, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2)) (\$MN)

TABLE 211 DOW CHEMICAL: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q3)) (\$MN)

TABLE 212 DOW CHEMICAL: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q3)) (\$MN)

TABLE 213 DOW CHEMICAL: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) (\$MN)

TABLE 214 DUPONT DE NEMOURS, INC: TOTAL REVENUE AND R&D EXPENSES,



(2020-2022(Q3)) (\$MN)

TABLE 215 DUPONT DE NEMOURS, INC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q3)) (\$MN)

TABLE 216 DUPONT DE NEMOURS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) (\$MN)

TABLE 217 EVONIK INDUSTRIES, AG: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q3)) (\$MN)

TABLE 218 EVONIK INDUSTRIES, AG: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q3)) (\$MN)

TABLE 219 EVONIK INDUSTRIES, AG: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) (\$MN)

TABLE 220 FRIESLAND CAMPINA GERMANY GMBH (DFE PHARMA): TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2))(\$MN)

TABLE 221 FRIESLAND CAMPINA GERMANY GMBH (DFE PHARMA): TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2))(\$MN)

TABLE 222 FRIESLAND CAMPINA GERMANY GMBH (DFE PHARMA): TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2))(\$MN)

TABLE 223 IFF, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2))(\$MN)

TABLE 224 IFF, INC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2))(\$MN)

TABLE 225 IFF, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2))(\$MN)

TABLE 226 KERRY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) (\$MN)

TABLE 227 KERRY GROUP: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2)) (\$MN)

TABLE 228 KERRY GROUP: TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022(Q2)) (\$MN)

TABLE 229 KERRY GROUP: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2)) (\$MN)



List Of Figures

LIST OF FIGURES

FIGURE 1 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) (\$MN)

FIGURE 2 RESEARCH METHODOLOGY: PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET

FIGURE 3 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH

FIGURE 4 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: FORECASTING MODEL

FIGURE 5 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 6 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SEGMENTATION FIGURE 7 INORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET SEGMENTATION

FIGURE 8 ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET SEGMENTATION FIGURE 9 MARKET DYNAMICS

FIGURE 10 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: PORTER'S ANALYSIS

FIGURE 11 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 12 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)

FIGURE 13 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON MOLECULE TYPE, 2022 (%)

FIGURE 14 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)

FIGURE 15 PLANT-BASED EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 16 MINERAL-BASED EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 17 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 18 INORGANIC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 19 INORGANIC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)



FIGURE 20 CALCIUM SALT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 21 CALCIUM SALT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 22 CALCIUM CARBONATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)

FIGURE 23 GCC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 24 PCC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 25 OTHER CALCIUM SALT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 26 METALLIC OXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 27 METALLIC OXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 28 TITANIUM DIOXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 29 OTHER METALLIC OXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 30 SILICATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 31 ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 32 CARBOHYDRATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 33 CARBOHYDRATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 34 SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 35 SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 36 ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 37 ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 38 LACTOSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 39 SUCROSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON



REGION, (2022 V/S 2029) (%)

FIGURE 40 SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 41 STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 42 MODIFIED STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 43 DRIED STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 44 CONVERTED STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 45 CELLULOSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 46 CELLULOSE ETHER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 47 CELLULOSE ESTER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 48 CROSCARMELLOSE SODIUM EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 49 MICROCRYSTALLINE CELLULOSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 50 PETROCHEMICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 51 GLYCOL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 52 OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 53 OTHER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 54 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON FUNCTIONALITY (2022 V/S 2029) (%)

FIGURE 55 SOLVENT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 56 COLORANT, FLAVORING & SWEETENER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 57 LUBRICANT & GLIDANT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 58 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)



FIGURE 59 SOLID DOSAGE FORM GLOBAL MARKET SHARE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (%)

FIGURE 60 GRANULATION GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 61 INJECTABLES DOSAGE FORM GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)

FIGURE 62 INJECTABLES DOSAGE FORM GLOBAL MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION, (2022 V/S 2029) (%)

FIGURE 63 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) (\$MN), CAGR (%)

FIGURE 64 PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, REVENUE BASED ON COUNTRY (2022) (%)(\$MN)

FIGURE 65 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)

FIGURE 66 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 67 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 VS 2029) (%)

FIGURE 68 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)

FIGURE 69 NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)

FIGURE 70 U.S. PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) (\$MN)

FIGURE 71 U.S. PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 72 U.S. SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 73 U.S. PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 74 REST OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) (\$MN)

FIGURE 75 REST OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 76 REST OF NORTH AMERICA SOLID DOSAGE FORMS MARKET

REVENUE BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 77 REST OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 78 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED



ON SOURCE (2022 V/S 2029) (%)

FIGURE 79 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 80 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 VS 2029) (%)

FIGURE 81 EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022) (%), CAGR (%)

FIGURE 82 EUROPEAN PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)

FIGURE 83 GERMANY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) (\$MN)

FIGURE 84 GERMANY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 85 GERMANY SOLID DOSAGE FORM MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 86 GERMANY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 87 FRANCE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 88 FRANCE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 89 FRANCE SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 90 FRANCE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 91 ITALY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 92 ITALY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 93 ITALY SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 94 ITALY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 95 REST OF EUROPE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 96 REST OF EUROPE PHARMACEUTICAL EXCIPIENTS MARKET

REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 97 REST OF EUROPE SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)



FIGURE 98 REST OF EUROPE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 99 APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)

FIGURE 100 APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)

FIGURE 101 APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 V/S 2029) (%)

FIGURE 102 APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)

FIGURE 103 APAC PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)

FIGURE 104 CHINA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) (\$MN)

FIGURE 105 CHINA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 106 CHINA SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 107 CHINA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 108 INDIA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) (\$MN)

FIGURE 109 INDIA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 110 INDIA SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 111 INDIA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022) (\$MN), CAGR (%)

FIGURE 112 JAPAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 113 JAPAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 114 JAPAN SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 115 JAPAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 116 REST OF APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) (\$MN)

FIGURE 117 REST OF APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE,



BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 118 REST OF APAC SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 119 REST OF APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 120 ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 VS 2029) (%)

FIGURE 121 ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)

FIGURE 122 ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 VS 2029) (%)

FIGURE 123 ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)

FIGURE 124 ROW PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY, (2022 V/S 2029) (%)

FIGURE 125 BRAZIL PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 126 BRAZIL PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 127 BRAZIL SOLID DOSAGE MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 128 BRAZIL PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 129 REST OF LATAM PHARMACEUTICAL EXCIPIENTS MARKET

REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 130 REST OF LATAM PHARMACEUTICAL EXCIPIENTS MARKET

REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 131 REST OF LATAM SOLID DOSAGE FORMS MARKET REVENUE.

BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 132 REST OF LATAM PHARMACEUTICAL EXCIPIENTS MARKET

REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)

FIGURE 133 MIDDLE EAST & OTHERS PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) (\$MN)

FIGURE 134 MIDDLE EAST & OTHERS PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) (\$MN)

FIGURE 135 MIDDLE EAST & OTHERS SOLID DOSAGE FORMS MARKET

REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (\$MN)

FIGURE 136 MIDDLE EAST & OTHERS PHARMACEUTICAL EXCIPIENTS MARKET

REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) (\$MN)



FIGURE 137 SWOT: ASHLAND, INC.

FIGURE 138 SWOT: ASSOCIATED BRITISH FOODS, PLC (SPI PHARMA)

FIGURE 139 SWOT: BASF SE

FIGURE 140 SWOT: CRODA INTERNATIONAL, PLC.

FIGURE 141 SWOT: DOW CHEMICAL

FIGURE 142 SWOT: DUPONT DE NEMOURS, INC.

FIGURE 143 SWOT: EVONIK INDUSTRIES, AG

FIGURE 144 SWOT: FRIESLAND CAMPINA

FIGURE 145 SWOT: INTERNATIONAL FLAVORS & FRAGRANCES, INC. (IFF)

FIGURE 146 SWOT: KERRY GROUP



I would like to order

Product name: Pharmaceutical Excipients Global Market - Forecast To 2029

Product link: https://marketpublishers.com/r/P9741C588EFEN.html

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P9741C588EFEN.html